IP Library Granted Patent US 9,969,976
Granted Patent B2
US 9,969,976 · App. 13/503,542 · Granted May 15, 2018

Cell populations having immunoregulatory activity, methods for the preparation and uses thereof

Inventors: Dirk Buescher (Madrid, ES); Olga De La Rosa (Madrid, ES)
Assignee: CELLERIX, S.A.
C12N5/0637A61K2035/122C12N2501/23C12N2502/1323C12N2502/1382
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,969,976
App. No.
13/503,542
Granted
May 15, 2018
Kind
B2
Abstract

A method for the preparation and/or generation of immunomodulatory cells which comprises contacting a mesenchymal stem cell (MSC) and/or fibroblast cell population with peripheral blood leukocytes for between about 2 hours and about 25 days is described herein.

Claims (9)

1. A method for the preparation and/or generation of regulatory T cells which comprises contacting a mesenchymal stem cell (MSC) population derived from adipose tissue and which does not express indoleamine 2,3-dioxygenase (IDO) constitutively, with peripheral blood leukocytes for between 10 days and 18 days in the presence of IL-2.

2. The method according to claim 1 wherein the regulatory T cells are selected from CD4+ cells and CD25+ cells.

3. A method for the preparation and/or generation of regulatory T cells which comprises contacting a MSC population derived from adipose tissue and which does not express indoleamine 2,3-dioxygenase (IDO) constitutively, with peripheral blood leukocytes in the presence of IL-2 and at least one further agent selected from the group consisting of lipopolysaccharide (LPS), IL-4, and GM-CSF for between 10 days and 18 days.

4. The method according to claim 3 wherein said further agent is LPS.

5. The method according to claim 3 wherein said further agents are IL-4 and GM-CSF.

6. A method for the preparation and/or generation of regulatory T cells specific for a chosen antigen or group of antigens, which comprises contacting a MSC population derived from adipose tissue and which does not express indoleamine 2,3-dioxygenase (IDO) constitutively, with peripheral blood leukocytes and a chosen antigen or group of antigens in the presence of IL-2 and at least one further agent selected from the group consisting of lipopolysacharide (LPS), IL-4, and GM-CSF for between 10 days and 18 days.

7. A method for the preparation and/or generation of regulatory T cells specific for a chosen antigen or group of antigens, which comprises

(a) contacting peripheral blood leukocytes with said chosen antigen or group of antigens in the presence of IL-2 and at least one further agent selected from the group consisting of lipopolysaccharide (LPS), IL-4, and GM-CSF,

(b) bringing said cell population into contact with a MSC population derived from adipose tissue and which does not express indoleamine 2,3-dioxygenase (IDO) constitutively for between 10 days and 18 days.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 7, 2021
From: TIGENIX, S.A.U.
To: TAKEDA PHARMACEUTICAL COMPANY LIMITED
Reel/Frame 058320/0042 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 19, 2012
From: BUESCHER, DIRK; DE LA ROSA, OLGA
To: CELLERIX S.A.
Reel/Frame 029156/0949 →
Priority Claims (1)
GB 0918615.6 · Oct 23, 2009 · national
Continuity (1)
Related Publication 20130052174A1 · Feb 28, 2013